08/23/2022

Meet with NETRIS Pharma at the ESMO Congress in Paris (September 9-13, 2022)

Reading : 1 min

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering dependence receptors-based drug discovery and development, is confirming that :

  • CEO and Founder Patrick Mehlen,
  • CMO Frédéric Le Bras, and
  • CFO Christophe Guichard,

will be attending the ESMO Congress taking place September 9-13, 2022, in Paris. Come and meet with us !

For any information, please send an email to  christopheguichard@netrispharma.com

All details at : https://www.esmo.org/meetings/esmo-congress-2022

Suggested articles

logo1
12/19/2023

NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors

NETRIS Pharma extends Series A to €24.4 million with €7.5 million equity injection Proceeds to enable the completion of 5 ongoing phase 2 clinical studies Reinforces its leadership team and Board of Directors

Reading : 5 min
logo Nature article
08/26/2023

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

Reading : 10 min
logo Nature article
08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min